Health and Healthcare

All Health and Healthcare Articles

Newest first · Page 350

Another Stent Failure For Boston Scientific (BSX)

Investors have another reason to bail out of Boston Scientific (BSX). It has been in a battle with the medical research community for over a year fighting the perception that its drug-coated stents may…

Douglas A. McIntyre · 18 years ago

Eli Lilly’s (LLY) Gift To The Funeral Industry

The National Funeral Directors Association must be sending “thank you” cards to Eli Lilly (LLY) and it partner Amylin (AMLN). Together, the companies developed and market diabetes drug Byetta. The firms had told the…

Douglas A. McIntyre · 18 years ago

Biodel & Backers Tapping Cash Via Equity Sale (BIOD)

Biodel Inc. (NASDAQ: BIOD) has filed with the SEC to sell up to 8.5 million shares of common stock.  The company will sell 5.5 million of the shares and 3 million of the shares…

Douglas A. McIntyre · 18 years ago

Alpharma Already Wants More From King (ALO, KG)

Alpharma, Inc. (NYSE: ALO) has already responded to King Pharmaceuticals Inc. (NYSE: KG) regarding the $33.00 per share offer made by King to acquire Alpharma.  As we noted based upon the premium trading to…

Douglas A. McIntyre · 18 years ago

Eil Lilly (LLY) Death Drug Needs More Regulation

If there wasn’t enough already wrong with the FDA drug approval process, diabetes drug Byetta, created for patients by Elli Lilly (LLY) and Amylin Pharmaceuticals (AMLN) is killing more people. The news follows an…

Douglas A. McIntyre · 18 years ago

Illumina Gets Secondary Behind It (ILMN)

Illumina Inc. (NASDAQ: ILMN) has priced its proposed secondary offering of 3.5 million shares at $87.50 per share.  This will result in net proceeds of roughly $297.9 million. The sole manager of the offering…

Douglas A. McIntyre · 18 years ago

Alnylam Cancels Conference… What’s Brewing? (ALNY)

We just saw a report out of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) that may get traders moving on both sides of the stock.  The company has just announced that management will not be presenting…

Douglas A. McIntyre · 18 years ago

CardioNet Defies Prior Secondary Trends (BEAT)

CardioNet, Inc. (NASDAQ: BEAT) is holding up rather well considering the discount pricing of a secondary offering.  The company sold 5 million shares at a price of $26.50 per share.  All shares were being…

Douglas A. McIntyre · 18 years ago

Align’s Guidance: Wearing a Retainer in Public (ALGN)

Align Technology Inc. (NASDAQ: ALGN) has just posted some mixed earnings.  Regardless of Wall Street’s and Main Street’s love of Invisalign, the stock is being pounded.  The company reported earnings at $0.06 EPS on…

Douglas A. McIntyre · 18 years ago

Amgen Defying Earnings Concerns (AMGN)

Earnings out of Amgen Inc. (NASDAQ: AMGN) appear to be strong enough to defy any notions that the big osteoporosis news would render this particular earnings report immaterial. The biotech giant just posted adjusted…

Douglas A. McIntyre · 18 years ago

Amgen Earnings Now A Coin Toss? (AMGN)

After today’s close, we’ll be getting earnings out of biotech giant Amgen Inc.  (NASDAQ: AMGN).  It’s amazing how the company’s strong osteoporosis data has suddenly gotten the company out of the gutter and suddenly…

Douglas A. McIntyre · 18 years ago